Further bioinformatic efforts (i.e. retrieving RNAseq data from TCGA database to precisely define PIK3CD-L and PIK3CD-S expression levels in cancer patients from selected cohorts) may facilitate our understanding on whether PIK3CD-S/PIK3CD-L or PI3Kδ-S/PI3Kδ-L expression ratios would correlate with the poorer survival rates and/or disease aggressiveness (i.e. drug resistance, recurrence, metastasis, and etc.)in endocrine cancers. The gene discussed is PIK3CD; the disease is cancer.